Cadrenal Therapeutics (CVKD) Rule 144 Notice — 500 Shares Proposed Sale

Rhea-AI Filing Summary

Cadrenal Therapeutics (CVKD) Form 144 notifies the SEC of a proposed sale of 500 common shares to be executed on or about 10/02/2025 through Merrill Lynch (Ponte Vedra Beach, FL) on the NASDAQ. The filing identifies Quang X. Pham as the seller and shows those 500 shares were originally acquired as Founders Shares on 01/25/2022. The filing also discloses a series of sales by the same person over the prior three months: 3,836 shares on 08/27/2025, 1,193 on 08/28/2025, 2,581 on 09/24/2025, 6,790 on 09/25/2025, 419 on 09/29/2025, and 881 on 10/01/2025, with gross proceeds listed for each sale. The filer certifies compliance with Rule 144 representations required by the form.

Positive

• Seller provided required Rule 144 notice, indicating procedural compliance for resale of restricted/control shares
• Acquisition date disclosed (01/25/2022 as Founders Shares), which clarifies holding period for the shares being sold

Negative

• Multiple recent insider sales disclosed: 3,836 (08/27/2025), 1,193 (08/28/2025), 2,581 (09/24/2025), 6,790 (09/25/2025), 419 (09/29/2025), 881 (10/01/2025)
• Pending sale of 500 shares on 10/02/2025 may further reduce insider holdings

Insights

Securities Compliance Expert

Form 144 documents a Rule 144 compliant notice for insider sales.

The filing shows a proposed sale of 500 common shares on 10/02/2025 via Merrill Lynch, and prior reported sales by the same person within the past three months.

This notice is the procedural disclosure required under Rule 144 to permit resale of restricted or control securities; it indicates the seller is following the rule's notice requirement rather than providing any new operational information about the issuer.

Corporate Governance Analyst

Multiple recent insider sales by the same person are disclosed in the filing.

The filing lists six separate sales between 08/27/2025 and 10/01/2025, with individual gross proceeds noted for each sale, showing ongoing disposition of shares by Quang X. Pham.

While the form does not state reasons for sales, the pattern of transactions is a factual disclosure investors can use to track insider liquidity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082	500	7066	2046854	10/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2022	Founders Shares	Issuer			500	01/25/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/27/2025	3836	53455.56
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/28/2025	1193	16540.64
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/24/2025	2581	36108
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/25/2025	6790	95661.94
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/29/2025	419	5869.5
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	10/01/2025	881	12343.19

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Cadrenal Therapeutics (CVKD) disclose?

The form discloses a proposed sale of 500 common shares on or about 10/02/2025 via Merrill Lynch, and lists prior sales by Quang X. Pham between 08/27/2025 and 10/01/2025 with gross proceeds for each sale.

Who is the seller listed on the CVKD Form 144?

The seller named in the filing is Quang X. Pham (address shown in the filing).

When were the shares being sold originally acquired?

The 500 shares to be sold were acquired as Founders Shares on 01/25/2022 according to the filing.

Which broker and exchange are named for the proposed sale?

The proposed sale lists Merrill Lynch (Ponte Vedra Beach, FL) as the broker and NASDAQ as the exchange.

Does the Form 144 include recent sale amounts and proceeds?

Yes. It lists six sales with amounts and gross proceeds, for example 3,836 shares on 08/27/2025 for $53,455.56 and 6,790 shares on 09/25/2025 for $95,661.94.